Universal Ibogaine Inc. focuses on developing and operating addiction treatment clinics in Canada, alongside conducting clinical trials for addiction therapies. Its financial health appears robust, with an impressive current and quick ratio of 72.43 and no debt, indicating strong liquidity. However, the stock's 50% decline today raises concerns about market sentiment and potential volatility. Despite its solid financial metrics, the low market cap of $1.56 million suggests challenges in attracting investor confidence, which could impact future growth prospects.
Loading financial metrics...
Company has $128K in cash but burned $241K last quarter. At this burn rate, only 0.5 quarters of runway remain without additional financing.
Gross profit margin declined from 100.0% to 30.5% year-over-year, suggesting pricing pressure or rising input costs are squeezing profitability.
Company posted a loss of $-1.7M over the last year, representing 107.0% of revenue.
Debt of $2.6M is 20.1x the company's cash position of $128K.
Operating cash flow has been negative for 3 consecutive quarters, burning $965K over the last year.
Exceptional revenue growth of 65.2% YoY demonstrates strong market demand and competitive positioning.
Valuation, risk assessment, competitive positioning, and key insights — all in one report.
Other Biotechnology companies of a similar size
Based on 2017-FY (Invalid Date)